How much is mavyret drugs cost off insurance?

how much is mavyret drugs cost off insurance
If you are concerned about the price of MAVYRET, you have choices. – * Cure is defined as no detectable hep C virus in the blood three months after therapy finishes. Individual outcomes might vary. As of January 2022, the advertised price, also known as the Wholesale Acquisition Cost (WAC), for one month of MAVYRET is $13,200.00.

If you have: You could pay:
$ 20
Medicaid $ 20 $20.00 or less per month, depending on state plan
Commercial Insurance (usually provided by employer) (Blue Cross Blue Shield, Aetna, etc) As little as $5 a month with MAVYRET Savings Card
Medicare: Part D $660.00-3,081.00 per month, depending on coverage phase Most Medicare patients have Standard Part D prescription coverage, which has different costs depending on deductibles and coverage gaps. An Insurance Specialist can help you understand what these costs mean to you, by calling 1-877-628-9738 . Monthly out-of-pocket cost for MAVYRET may vary depending on patient’s other medication costs.
Medicare: Low-Income Subsidy (LIS) $9.85 per month starting January 1, 2022
Uninsured or having difficulty paying for your medication myAbbVie Assist provides AbbVie medicines to qualifying patients. Visit or call 1-800-222-6885 to learn more.
Other Insurance (VA, DOD, TRICARE, others) Because coverage varies by plan, call 1-877-628-9738 to speak to an Insurance Specialist to find out how much MAVYRET will cost you.
*Important Details About Understanding Your Individual Costs: The chart above provides cost information based on what a person with the type of coverage listed may pay for a 4-week supply of MAVYRET. Your type of health or prescription insurance plan will determine exactly how much you will pay.

How does Mavyret make you feel?

Will taking Mavyret make me feel sick? It is possible. Common adverse reactions of Mavyret include nausea, headache, drowsiness, and diarrhea. These side effects may cause you to feel ill. Consult your doctor if you feel ill or experience side effects that worsen or persist while taking Mavyret.

Can Hep C return after a decade?

After completing treatment for hepatitis C with direct-acting antivirals (DAAs) and being deemed cured, is it okay to consume alcohol socially? – Answer From Stacey A. Rizza, M.D. Recent hepatitis C medicines, known as direct-acting antivirals (DAAs), have not been in use long enough for researchers to address this issue.

Those who are concerned about their liver health should avoid alcohol as a general rule. A few studies have already demonstrated that certain liver problems persist for years following effective DAA therapy. In addition, several previous research demonstrate that alcohol exacerbates chronic hepatitis C-related liver damage and raises the associated long-term health concerns.

Here are a few of the results:

  • Liver fibrosis (fibrosis). Frequently, chronic hepatitis C infection results in hepatic fibrosis. This impact may be long-lasting following therapy. Even if you have a little amount of visible fibrosis, consuming alcohol may exacerbate the scarring, just as it does in persons without chronic hepatitis C.
  • Infection recurrence. It is conceivable, although uncommon, for hepatitis C infection to recur after apparent therapeutic success. Typically, relapses occur during the first several months after blood tests reveal the virus is no longer present. Occasionally, a relapse becomes apparent much later. Although the specific cause of relapse is unknown, the remote risk that the infection may recur is an additional reason to abstain from alcohol consumption.
  • Liver cancer risk. Damage to the liver caused by Hepatitis C raises the chance of liver cancer. This danger is mitigated by the elimination of the hepatitis C virus with DAA therapy. However, it does not lower the risk to that of a person with no history of hepatitis C. Alcohol use is associated with the development of liver cancer following hepatitis C treatment.

Dr. Stacey A. Rizza on January 22, 2022

  1. Tran A, et al. Diagnosis and monitoring of chronic hepatitis C virus infection without invasive procedures. Clinics and Research in Gastroenterology and Hepatology.
  2. Association for the European Study of the Liver. EASL guidelines on the treatment of hepatitis C: the series’ last update.2020 Journal of Hepatology
  3. 10.1016/j.jhep.2020.08.018
  4. Feldman M, et al., editors. Hepatitis C. Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, and Management. Elsevier
  5. 2021
  6. 11th edition Until November 15, 2021.
  7. CA Marshall et al. Hepatitis C with alcohol consumption. Until November 15, 2021.

See more Expert Answers